Compare ETN & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ETN | NVO |
|---|---|---|
| Founded | 1916 | 1923 |
| Country | Ireland | Denmark |
| Employees | 101000 | 69500 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.3B | 197.4B |
| IPO Year | 2012 | N/A |
| Metric | ETN | NVO |
|---|---|---|
| Price | $406.90 | $47.39 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 22 | 11 |
| Target Price | ★ $401.95 | $51.00 |
| AVG Volume (30 Days) | 2.4M | ★ 11.4M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | 1.07% | ★ 3.19% |
| EPS Growth | ★ 10.00 | N/A |
| EPS | ★ 2.22 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.72 | N/A |
| Revenue Next Year | $9.54 | $3.70 |
| P/E Ratio | $195.29 | ★ $13.60 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $311.92 | $35.12 |
| 52 Week High | $436.74 | $71.80 |
| Indicator | ETN | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 50.50 | 64.78 |
| Support Level | $355.03 | $45.62 |
| Resistance Level | $408.45 | $47.79 |
| Average True Range (ATR) | 14.34 | 1.41 |
| MACD | 1.97 | 0.28 |
| Stochastic Oscillator | 50.45 | 99.14 |
Founded in 1911 by Joseph Eaton, the eponymous company began by selling truck axles in New Jersey. Eaton has since become an industrial powerhouse largely through acquisitions in various end markets. Eaton's portfolio can broadly be divided into two parts: its electrical and industrial businesses. Its electrical portfolio (representing around 70% of company revenue) sells components within data centers, utilities, and commercial and residential buildings, while its industrial business (30% of revenue) sells components within commercial and passenger vehicles and aircraft. Eaton receives favorable tax treatment as a domiciliary of Ireland, but it generates over half of its revenue within the US.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.